Phase 1 , Placebo-Controlled, Dose-Ranging Trial to Determine Safety and Immunogenicity of an Oral Adenoviral-Vector Based Influenza B Vaccine

Trial Profile

Phase 1 , Placebo-Controlled, Dose-Ranging Trial to Determine Safety and Immunogenicity of an Oral Adenoviral-Vector Based Influenza B Vaccine

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

At a glance

  • Drugs VXA BYW-10 (Primary)
  • Indications Influenza B virus infections
  • Focus Adverse reactions
  • Sponsors Vaxart
  • Most Recent Events

    • 08 May 2017 Planned End Date changed from 1 May 2017 to 4 Oct 2018.
    • 08 May 2017 Planned primary completion date changed from 1 Sep 2016 to 5 Oct 2017.
    • 09 Jul 2016 Planned End Date changed from 1 Jan 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top